Pragmatic’s Imprinted Logic Moving into Commercial Production
News Jan 30, 2012
PragmatIC Printing Ltd has announced plans to move its technology to pilot-scale production under an agreement with The Centre for Process Innovation (CPI).
As well as supporting commercial production for low volume applications, the pilot line also provides a platform for the collaborative PragmatIC Pilot Production Program (P4).
Building on PragmatIC’s highly successful prototyping activities throughout 2011, P4 will involve the entire value chain for deployment of PragmatIC’s technology - including licensees for high volume production, complementary technology providers, systems integrators such as converters and labellers, and end users including major brand owners.
Further details on P4 are available from PragmatIC on a confidential basis.
A key advantage of PragmatIC’s approach to printed logic is that it delivers unrivalled density and performance in a unique form factor, while employing mature, proven processes and readily available equipment.
This approach enables a rapid transition to commercial production, with the pilot line intended to commence operation by the fourth quarter of 2012.
Scott White, Chief Executive Officer of PragmatIC Printing, stated: “We are hugely excited at taking this next tangible step towards commercial deployment of our unique technology for imprinted logic. We welcome interest from all those in the industry who want to make printed electronics products a reality, and encourage collaborative participation in our P4 initiative.”
Tom Taylor, CPI’s Director of Printable Electronics, added: “We are keen to leverage our extensive facilities and expertise to assist PragmatIC Printing in moving to commercial production. The P4 initiative is also highly complementary with other activities at CPI, in particular the Integrated Smart Systems line which is ideally suited to combine PragmatIC’s imprinted logic with other printing and electronics technologies to deliver innovative finished products.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018